IL140917A0 - Human anti-factor ix/ixa antibodies - Google Patents

Human anti-factor ix/ixa antibodies

Info

Publication number: IL140917A0
Authority: IL; Israel
Prior art keywords: factor; ixa; fix; human anti; inhibiting
Prior art date: 1998-08-28

Application number

IL14091799A

Other languages

English (en)

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-28

Filing date

1999-08-26

Publication date

2002-02-10

1999-08-26 Application filed by Genentech Inc filed Critical Genentech Inc

2002-02-10 Publication of IL140917A0 publication Critical patent/IL140917A0/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)

IL14091799A 1998-08-28 1999-08-26 Human anti-factor ix/ixa antibodies IL140917A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9823398P	1998-08-28	1998-08-28
US12276799P	1999-03-03	1999-03-03
PCT/US1999/019453 WO2000012562A1 (en)	1998-08-28	1999-08-26	HUMAN ANTI-FACTOR IX/IXa ANTIBODIES

Publications (1)

Publication Number	Publication Date
IL140917A0 true IL140917A0 (en)	2002-02-10

Family

ID=26794469

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14091799A IL140917A0 (en)	1998-08-28	1999-08-26	Human anti-factor ix/ixa antibodies

Country Status (15)

Country	Link
US (3)	US6624295B1 (de)
EP (1)	EP1107996B1 (de)
JP (1)	JP4638035B2 (de)
CN (1)	CN1183160C (de)
AT (1)	ATE217889T1 (de)
AU (1)	AU766551C (de)
BR (1)	BR9913435A (de)
CA (1)	CA2341276C (de)
DE (1)	DE69901569T2 (de)
DK (1)	DK1107996T3 (de)
ES (1)	ES2177316T3 (de)
IL (1)	IL140917A0 (de)
NZ (1)	NZ509430A (de)
PT (1)	PT1107996E (de)
WO (1)	WO2000012562A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT411997B (de) *	1999-09-14	2004-08-26	Baxter Ag	Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE0000675D0 (sv) *	2000-03-02	2000-03-02	Protease Ab	Monoclonal antibodies
DE10012732A1 (de) *	2000-03-18	2001-09-20	Aventis Behring Gmbh	Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
KR20070116192A (ko) *	2000-05-15	2007-12-06	스미스클라인 비참 코포레이션	항혈전제
GB2378949B (en) *	2001-08-16	2005-09-07	Morten Steen Hanefeld Dziegiel	Recombinant anti-plasmodium falciparum antibodies
DE10311248A1 (de)	2003-03-14	2004-09-30	Müller-Hermelink, Hans Konrad, Prof. Dr.	Humaner monoklonaler Antikörper
GB0309126D0 (en) *	2003-04-17	2003-05-28	Neutec Pharma Plc	Clostridium difficile focussed antibodies
EP1531162A1 (de) *	2003-11-14	2005-05-18	Heinz Vollmers	Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
DE10353175A1 (de)	2003-11-14	2005-06-16	Müller-Hermelink, Hans Konrad, Prof. Dr.	Humaner monoklonaler Antikörper mit fettsenkender Wirkung
GB0414886D0 (en)	2004-07-02	2004-08-04	Neutec Pharma Plc	Treatment of bacterial infections
EP1905839B2 (de) *	2006-09-22	2019-07-10	Wacker Chemie AG	Verfahren zur fermentativen Herstellung von Proteinen
WO2010045388A2 (en) *	2008-10-14	2010-04-22	Dyax Corp.	Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
WO2011121020A1 (en) *	2010-03-30	2011-10-06	Octapharma Ag	A process for purifying vitamin k dependent proteins such as coagulation factor ix
KR101951446B1 (ko)	2010-03-30	2019-02-22	옥타파마 아게	성장 인자 단백질을 정제하는 방법
WO2011130324A1 (en) *	2010-04-13	2011-10-20	Medimmune, Llc	Fibronectin type iii domain-based multimeric scaffolds
WO2012161226A1 (ja) *	2011-05-23	2012-11-29	積水メディカル株式会社	Pivka-ii測定試薬における非特異反応の抑制方法
TWI617319B (zh) *	2015-09-01	2018-03-11	免疫功坊股份有限公司	用以治療病理性血栓的融合蛋白
IL267519B2 (en) *	2016-12-23	2025-04-01	Novartis Ag	Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease
EP3577140A1 (de)	2017-02-01	2019-12-11	Novo Nordisk A/S	Prokoagulatorische antikörper
US11220554B2 (en)	2018-09-07	2022-01-11	Novo Nordisk A/S	Procoagulant antibodies
CN115448985A (zh) *	2021-06-08	2022-12-09	上海循曜生物科技有限公司	新型抗栓抗体
CN116333145B (zh) *	2023-04-14	2023-11-07	北京基科晟斯医药科技有限公司	结合活化凝血因子ix的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3720983A1 (de) *	1987-06-25	1989-01-05	Hoechst Ag	Immunometrisches bestimmungsverfahren
AU7766391A (en)	1990-04-23	1991-11-11	Corvas International N.V.	Thrombus-specific antibody derivatives
DE69427928T3 (de)	1993-03-05	2012-05-10	Bayer Healthcare Llc	Humane monoklonale anti-TNF alpha Antikörper
PT699237E (pt)	1994-03-17	2003-07-31	Merck Patent Gmbh	Fvs de cadeia anti-egfr e anticorpos anti-egfr
MA24512A1 (fr) *	1996-01-17	1998-12-31	Univ Vermont And State Agrienl	Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

1999
- 1999-08-26 US US09/383,667 patent/US6624295B1/en not_active Expired - Lifetime
- 1999-08-26 BR BR9913435-7A patent/BR9913435A/pt not_active IP Right Cessation
- 1999-08-26 WO PCT/US1999/019453 patent/WO2000012562A1/en not_active Ceased
- 1999-08-26 DK DK99943928T patent/DK1107996T3/da active
- 1999-08-26 IL IL14091799A patent/IL140917A0/xx not_active IP Right Cessation
- 1999-08-26 PT PT99943928T patent/PT1107996E/pt unknown
- 1999-08-26 AT AT99943928T patent/ATE217889T1/de active
- 1999-08-26 EP EP99943928A patent/EP1107996B1/de not_active Expired - Lifetime
- 1999-08-26 ES ES99943928T patent/ES2177316T3/es not_active Expired - Lifetime
- 1999-08-26 CN CNB998100838A patent/CN1183160C/zh not_active Expired - Lifetime
- 1999-08-26 CA CA002341276A patent/CA2341276C/en not_active Expired - Lifetime
- 1999-08-26 DE DE69901569T patent/DE69901569T2/de not_active Expired - Lifetime
- 1999-08-26 JP JP2000567575A patent/JP4638035B2/ja not_active Expired - Lifetime
- 1999-08-26 AU AU56923/99A patent/AU766551C/en not_active Expired
- 1999-08-26 NZ NZ509430A patent/NZ509430A/en not_active IP Right Cessation
2003
- 2003-07-08 US US10/614,959 patent/US7049411B2/en not_active Expired - Lifetime
2006
- 2006-03-31 US US11/396,115 patent/US7354585B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT1107996E (pt)	2002-10-31
US6624295B1 (en)	2003-09-23
US20060088534A1 (en)	2006-04-27
EP1107996B1 (de)	2002-05-22
US7354585B2 (en)	2008-04-08
JP2002523081A (ja)	2002-07-30
CN1183160C (zh)	2005-01-05
CN1317015A (zh)	2001-10-10
JP4638035B2 (ja)	2011-02-23
DE69901569T2 (de)	2002-12-19
US7049411B2 (en)	2006-05-23
AU5692399A (en)	2000-03-21
AU766551C (en)	2005-02-17
NZ509430A (en)	2002-04-26
CA2341276A1 (en)	2000-03-09
BR9913435A (pt)	2001-09-25
CA2341276C (en)	2005-10-11
ATE217889T1 (de)	2002-06-15
WO2000012562A1 (en)	2000-03-09
AU766551B2 (en)	2003-10-16
DK1107996T3 (da)	2002-09-16
ES2177316T3 (es)	2002-12-01
EP1107996A1 (de)	2001-06-20
DE69901569D1 (de)	2002-06-27
US20060193851A1 (en)	2006-08-31

Legal Events

Date	Code	Title
2008-08-10	FF	Patent granted
2008-08-10	KB	Patent renewed
2010-04-08	KB	Patent renewed
2013-08-29	KB	Patent renewed
2017-07-31	KB	Patent renewed
2020-03-31	EXP	Patent expired

Publication	Publication Date	Title
IL140917A0 (en)	2002-02-10	Human anti-factor ix/ixa antibodies
MXPA03005273A (es)	2003-09-25	Anticuerpos producidos procarioticamente y sus usos.
ID29393A (id)	2001-08-30	Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
AU2001283343A1 (en)	2002-04-02	Adhesive compositions including self-assembling molecules, adhesives, articles, and methods
BG102071A (en)	1998-09-30	Minor molecule inhibitors of rotamase enzymic activity
MY136095A (en)	2008-08-29	Use of human anti-ctla-4 antibodies for treatment of cancer
ATE286053T1 (de)	2005-01-15	Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
IL127558A0 (en)	1999-10-28	Hepatocyte growth factor receptor agonists and uses thereof
MXPA03006771A (es)	2004-05-05	Anticuerpos modificados y metodos de uso.
TR199903331T2 (xx)	2000-06-21	Farnesil protein transferas engelleyicileri.
PL1644504T3 (pl)	2010-08-31	Warianty czynnika VII lub VIIa domeny Gla
BR0007527A (pt)	2001-12-04	Fenilfenantridinas com atividade inibitória depde-iv
ZA979961B (en)	1999-05-05	5-HT1F agonists
PL343245A1 (en)	2001-07-30	Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
GB0111186D0 (en)	2001-06-27	Novel compounds
DE60013098D1 (de)	2004-09-23	Zusammensetzung zur hautdesinfizierung
HU9700903D0 (en)	1997-07-28	Sulfonamide-substituted chromanes, process for producing them, their use as pharmaceutical compositions or diagnostica, and pharmaceutical compositions containing them
YU13301A (sh)	2005-06-10	Muskarinski agonisti i antagonisti
TR199700999T1 (xx)	1998-01-21	Askomisinler.
SE9802937D0 (sv)	1998-09-01	Novel compounds
PL316656A1 (en)	1997-02-03	Free halophantrin base for use in treating marsh-fever and compositions containing same
IL144199A0 (en)	2002-05-23	Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
BG105003A (en)	2001-07-31	Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer
TR200200278T2 (tr)	2002-06-21	Kalsilitik bileşimler
EP1303300A4 (de)	2004-03-24	Zusammensetzungen und methoden zur behandlung von candidosen